Recent studies in patients with moderate PD have demonstrated that beneficial GLP-1R-mediated actions translate to humans [18] with actions being mediated via brain insulin-signaling proteins, Akt and mechanistic target of rapamycin (mTOR) pathways. This evidence concerns the gene AKT1 and Parkinson disease.